ClinicalTrials.gg
RecruitingNCT07238686Updated Oct 9, 2026

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

A Phase 2 interventional study of Venetoclax and Azacitidine (AZA) or Decitabine (DAC) in Myelodysplastic Syndromes, sponsored by Beijing 302 Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Beijing 302 Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2025, registered Nov 2025).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies testing venetoclax in Myelodysplastic Syndromes — 17 open to participants now, 27 under way, 2 of them phase 3. venetoclax · Myelodysplastic Syndromes.

Planned enrollment
25th of 40
40 · median 58
Started
2025
with 4 others
Phase 2
16 of 40
9 open now
Primary completion
2030-06
later than 26 of 26 live
Registered
40th of 40
by date
Lead sponsor
2 of 40
Beijing 302 Hospital

Among the 40 studies testing venetoclax in Myelodysplastic Syndromes, this one is the 25th largest by planned enrollment, is one of 5 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 26 of the 26 other live ones, and was the 40th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

17 of the 40 studies testing venetoclax in Myelodysplastic Syndromes are open now, in 6 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing venetoclax in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • venetoclax
  • hypomethylating agent
  • GPBMC infusion
  • microtransplant
  • microtransplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years, male or female, non-limited by race or ethnicity.
  • Confirmed diagnosis of MDS according to the World Health Organization (WHO) 5th edition classification, based on histopathology and cytogenetics.
  • Risk stratification according to the Revised International Prognostic Scoring System (IPSS-R) must place the patient in the intermediate-, high-, or very high-risk category.
  • Not candidates for or refuse hematopoietic stem cell transplantation.
  • Adequate hepatic function including (ALT) and aspartate aminotransferase (AST )\<= 3 × (ULN), and total \<= 1.5 × ULN.
  • Adequate renal function including serum creatinine \<= 2 × ULN or >= 40mL/min.
  • measured by echocardiogram is within the normal range (LVEF > 50%).
  • The subject must have one donor who is >= 18 years old and HLA matched at 0-7/10 loci (i.e., at least 3 HLA loci must be mismatched). In addition, the donor voluntarily donates hematopoietic stem cells and signs the consent form.
  • Each subject (or his/her legal representatives) must sign the Form (ICF), indicating that he/she understands the purpose and procedures of research, and is willing to participate in research.
  • Donor inclusion criteria: The donor meets the institution's criteria for related peripheral blood hematopoietic stem cell donors. The donor must be able to tolerate the cell separation and collection process, and sign the Informed Consent Form.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled infection or hemorrhage.
  • Cardiovascular disease with clinical significance, such as uncontrolled or highly symptomatic cardiac arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or (NYHA) function class 3 (moderate) or class 4 (severe) heart disease.
  • Uncontrolled disease or requiring treatment.
  • History of severe blood infusion reaction.
  • Nursing women, women of with positive urine pregnancy test, or women of childbearing potential who are not willing to maintain adequate .
  • Psychiatric disorder or cognitive impairment that in the researcher's judgment would make the subject not likely to adhere to the protocol requirements.
  • Major surgery within 4 weeks prior to enrollment.
  • Life-threatening illness other than MDS or uncontrolled intercurrent illness.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    This cohort includes patients with intermediate-risk and higher MDS who are ineligible for or refuse allogeneic HSCT. Patients receive Venetoclax in combination with hypomethylating agent and HLA-mismatched donor GPBMC infusion. Treatment cycles are 28 days, repeated until disease progression or unacceptable toxicity.

    Drug: Venetoclax · Drug: Azacitidine (AZA) or Decitabine (DAC) · Biological: GPBMC infusion

Interventions

  • Given PO. For the first cycle, dose of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Days 3-14. For other cycles, dose of 400 mg on Days 1-14. Note: The dose should be reduced to 100-200 mg daily if concomitant azole antifungals are required.

  • DrugDecitabineStudies of DecitabineDecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AZA: Given SC. Dose of 75 mg/m² on Days 1-7 of each cycle. DAC: Given IV. Dose of 20 mg/m² on Days 1-5 of each cycle.

  • BiologicalGPBMC infusion

    HLA-mismatched donor GPBMCs are infused on Day 15.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is defined as the number of days from the date of study entry to the date of death.

    Time frame: Measured up to 4 years after the last participant is enrolled

  2. Overall response rate (ORR)

    ORR is defined as complete remission (CR) (or CR equivalent) + partial remission (PR) + CR with limited count recovery (CRL) + CR with partial hematologic recovery (CRh) + hematologic improvement (HI) according to IWG 2023 criteria.

    Time frame: Measured up to 2 years after the last participant is enrolled

Secondary outcomes

  1. Modified overall response (mOR)

    Modified OR is defined as CR+PR+CRL+CRh.

    Time frame: Measured up to 2 years after the last participant is enrolled

  2. Complete remission (CR)

    CR is defined as absolute neutrophil count \> 1 × 109/L, platelet count \> 100 × 109/L, Hb ≥10 g/dL, bone marrow with \< 5% blasts, and PB blasts 0%.

    Time frame: Measured up to 2 years after the last participant is enrolled

  3. Partial remission (PR)

    PR is defined as decrease of at least 50% in the percentage of blasts still ≥5% in the bone marrow, peripheral blood neutrophil count \> 1 × 109/L, platelet count \> 100 × 109/L, Hb ≥10 g/dL.

    Time frame: Measured up to 2 years after the last participant is enrolled

  4. CR with limited count recovery (CRL)

    CRL is defined as bone marrow with less than 5% blasts, PB blasts 0%, and PB only meeting 1 or 2 of the following: absolute neutrophil count \> 1 × 109/L, platelet count \> 100 × 109/L, Hb ≥10 g/dL.

    Time frame: Measured up to 2 years after the last participant is enrolled

  5. CR with partial hematologic recovery (CRh)

    CRh is defined as bone marrow with less than 5% blasts, and PB not meeting criteria for CR or CRL, no Hb threshold required, platelets ≥50 × 109/L, neutrophils ≥0.5 × 109/L, blasts 0%.

    Time frame: Measured up to 2 years after the last participant is enrolled

  6. Progression-free survival (PFS)

    PFS is defined as the number of days from the date of study entry to the date of the first of the following events: progressed disease; relapse from CR (or CR equivalent), PR, CRL, CRh, or HI; death from any cause.

    Time frame: Measured up to 4 years after the last participant is enrolled

  7. Treatment-related mortality (TRM)

    TRM is defined as the death related to treatment instead of disease progression.

    Time frame: Measured up to 2 years after the last participant is enrolled

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2030, 60 months after the start.

Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 60 months is below that.

Counting every sponsor, half of 279 studies reached it within 65 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartActual
Jun 20, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2031
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07238686
Lead sponsor
Beijing 302 Hospital
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Jun 20, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Oct 9, 2026

Study contacts

Bo Cai, MD
Contact
caibo2008@163.com
+861066947168
Fei Peng, MD
Contact
pengfei0118@foxmail.com
+861066947180
Bo Cai, MD
principal investigator · Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion